SAN FRANCISCO, March 4, 2013 (GLOBE NEWSWIRE) -- CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, and Projects In Knowledge, Inc., a leading developer of point-of-care digital and mobile information tools and continuing medical education (CME/CE) programs, today announced a multi-year partnership agreement to jointly distribute informational point-of-care software applications to the more than 35,000 oncologists and other clinicians in the Projects In Knowledge clinician network.
The partnership will focus initially on integrating CollabRx Therapy Finder™ products into the Projects In Knowledge @Point of Care360™ platform. Therapy Finder applications are decision support tools that enable oncologists and pathologists to take into account the genetics of a patient's tumor when determining a treatment plan. The @Point of Care360 platform is a next-generation interactive medical textbook that provides point-of-care accessibility to educational resources and allows clinicians to access a robust and easily searchable knowledge base.
"This partnership with CollabRx and use of its Therapy Finder products, which we believe are 'best of breed', supports our goal to add tools at the point of care that help the clinician in achieving positive patient outcomes," said Robert Stern, CEO of Projects In Knowledge.
CollabRx and Projects In Knowledge will seek support from pharmaceutical and biotechnology companies in the form of educational grants to conduct initial activities of the partnership. Extension of the partnership scope and the development of additional planned extensions of the integrated offering will be commercialized using other mechanisms.
"We are honored to be working with Projects In Knowledge to help oncologists deliver the best possible care to their patients," said Thomas Mika, President & CEO of CollabRx. "This agreement represents a significant milestone by CollabRx in facilitating access to its Therapy Finder product line by large numbers of practicing physicians to inform cancer treatment planning at the point of care."
CollabRx, Inc. (Nasdaq:CLRX) is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world's knowledge on genomics-based medicine with specific insights from the nation's top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.
The CollabRx, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=16990
About Projects In Knowledge
Projects In Knowledge is a fully accredited provider of cutting-edge educational programs for physicians and other clinicians. Since 1980, our mission has been to improve the quality of healthcare in the United States and abroad by delivering exceptional professional education, with demonstrated results, using creative, effective, and easily accessible instructional modalities. Learn more about us and view our CME/CE programs at www.projectsinknowledge.com.
CollabRx Safe Harbor Statement
This press release includes forward-looking statements about CollabRx's anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and CollabRx's plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by CollabRx with the Securities and Exchange Commission. CollabRx undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
CONTACT: CollabRx Contacts: Thomas R. Mika, CEO CollabRx, Inc. (415) 248-5350 Robert Ferri Partners, LLC Robert Ferri (415) 575-1589 (direct) firstname.lastname@example.org Projects In Knowledge Contact: Patty Peterson, CCMEP Senior Vice President Projects In Knowledge, Inc. (973) 200-2523 email@example.com